Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 101471195 Publication Model: Print Cited Medium: Internet ISSN: 1179-1993 (Electronic) Linking ISSN: 11782595 NLM ISO Abbreviation: Pharmaceut Med Subsets: MEDLINE

Publication: Auckland : Adis, Springer International
Original Publication: Auckland, N.Z. : Wolters Kluwer Health/Adis, 2008-

Liver Cirrhosis/*diagnosis ; Non-alcoholic Fatty Liver Disease/*pathology ; Obesity/*complications; Biomarkers/blood ; Biopsy/adverse effects ; Biopsy/economics ; Circulating MicroRNA/blood ; Disease Progression ; Elasticity Imaging Techniques/methods ; Gastrointestinal Microbiome ; Humans ; Liver/diagnostic imaging ; Liver/metabolism ; Liver/pathology ; Liver Cirrhosis/blood ; Liver Cirrhosis/epidemiology ; Liver Cirrhosis/pathology ; Metabolomics/methods ; Non-alcoholic Fatty Liver Disease/blood ; Non-alcoholic Fatty Liver Disease/diagnosis ; Non-alcoholic Fatty Liver Disease/etiology ; Obesity/blood ; Obesity/epidemiology ; Obesity/metabolism ; Observer Variation ; Predictive Value of Tests ; Prevalence ; Proteomics/methods ; Risk Assessment ; Severity of Illness Index ; United States

Nonalcoholic fatty liver disease (NAFLD) has now become a worldwide health issue due to the obesity epidemic, affecting approximately 90% of the obese population and 15-40% of the general population. It is the most common form of chronic liver disease in the United States. NAFLD constitutes a spectrum of diseases ranging in severity from mild, such as fatty liver, progressing into nonalcoholic steatohepatitis (NASH), then fibrosis, and ending with cirrhosis. NASH and increasing fibrosis stage are associated with increased morbidity and mortality; the fibrosis stage is therefore a critical element of risk stratification needed to determine therapeutic approach and also the response to treatment. Liver biopsy is considered the 'gold standard' in the diagnosis of NAFLD. However, it is not practical for widespread clinical use because it is invasive, costly, and associated with complications including occasional death. These limitations have driven the development of noninvasive tests that can accurately predict the fibrosis stage in those with NAFLD. In this review, we provide a concise overview of different non-invasive measurements used for NAFLD/NASH.

Cell Metab. 2017 May 2;25(5):1054-1062.e5. (PMID: 28467925)
J Hepatol. 2006 Jun;44(6):1167-74. (PMID: 16618517)
Pharmacol Rev. 2008 Sep;60(3):311-57. (PMID: 18922966)
Curr Med Imaging Rev. 2011 Nov;7(4):255-282. (PMID: 22308105)
Liver Int. 2015 Feb;35(2):429-37. (PMID: 25308921)
Dig Dis Sci. 2015 Nov;60(11):3318-28. (PMID: 26138654)
Dig Dis. 2010;28(6):756-75. (PMID: 21525761)
Scand J Gastroenterol. 2015 May;50(5):584-92. (PMID: 25639675)
Hepatology. 2005 Sep;42(3):665-74. (PMID: 16116632)
Nat Med. 2005 Feb;11(2):183-90. (PMID: 15685173)
Lab Invest. 2004 Feb;84(2):203-12. (PMID: 14661032)
Ann Gastroenterol. 2012;25(3):218-231. (PMID: 24714123)
PPAR Res. 2014;2014:432647. (PMID: 24772164)
F1000Res. 2018 Jun 11;7:. (PMID: 29946426)
Gut. 2010 Sep;59(9):1265-9. (PMID: 20801772)
Lipids Health Dis. 2014 Jul 21;13:116. (PMID: 25047818)
Hepatol Res. 2016 Aug;46(9):862-70. (PMID: 26763834)
J Ultrasound Med. 2014 Sep;33(9):1597-604. (PMID: 25154941)
Can J Gastroenterol Hepatol. 2014 Dec;28(11):607-18. (PMID: 25575111)
Exp Ther Med. 2011 Nov;2(6):1077-1081. (PMID: 22977624)
J Gastroenterol Hepatol. 2013 Apr;28(4):678-83. (PMID: 23215811)
Sci Rep. 2018 Aug 17;8(1):12414. (PMID: 30120271)
J Gastroenterol. 2007 May;42(5):375-81. (PMID: 17530362)
Hepatology. 2006 Sep;44(3):769; author reply 769-70. (PMID: 16941681)
Hepatology. 2018 May;67(5):2001-2012. (PMID: 29059456)
Hepatology. 2005 Jun;41(6):1313-21. (PMID: 15915461)
Gastroenterology. 2009 Jan;136(1):160-7. (PMID: 18992746)
World J Gastroenterol. 2015 Mar 21;21(11):3223-31. (PMID: 25805928)
Hepatology. 2017 Jan;65(1):78-88. (PMID: 27706836)
PLoS One. 2013 Dec 23;8(12):e84934. (PMID: 24376856)
Hepat Med. 2010 May 25;2:49-67. (PMID: 24367208)
Gut. 2008 Oct;57(10):1441-7. (PMID: 18390575)
BMC Gastroenterol. 2008 Nov 14;8:53. (PMID: 19014569)
J Clin Transl Hepatol. 2017 Sep 28;5(3):261-271. (PMID: 28936407)
Hepatology. 2016 Jun;63(6):1875-87. (PMID: 26849287)
Liver Int. 2010 Aug;30(7):1043-8. (PMID: 20492500)
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. (PMID: 19523535)
PLoS Pathog. 2010 Jan;6(1):e1000719. (PMID: 20062526)
Hepatology. 2016 Jun;63(6):1817-27. (PMID: 26659452)
World J Hepatol. 2018 Aug 27;10(8):530-542. (PMID: 30190781)
Clin Anat. 2010 Jul;23(5):497-511. (PMID: 20544947)
BMC Gastroenterol. 2006 Feb 14;6:6. (PMID: 16503961)
Dig Liver Dis. 2017 Oct;49(10):1133-1138. (PMID: 28572039)
BMJ. 2016 Sep 07;354:i4428. (PMID: 27605111)
Clin Mol Hepatol. 2012 Dec;18(4):383-90. (PMID: 23323254)
Clin Chim Acta. 1996 Aug 30;252(2):171-80. (PMID: 8853564)
J Gastroenterol Hepatol. 2011 Oct;26(10):1536-43. (PMID: 21950746)
J Clin Gastroenterol. 2009 Nov-Dec;43(10):985-9. (PMID: 19525859)
World J Gastroenterol. 2014 Jul 14;20(26):8325-40. (PMID: 25024592)
Adv Nutr. 2016 Jan 15;7(1):5-13. (PMID: 26773011)
J Magn Reson Imaging. 2017 Apr;45(4):1163-1170. (PMID: 27662640)
Gut. 2018 Dec;67(12):2204-2212. (PMID: 30177542)
Therap Adv Gastroenterol. 2018 Nov 15;11:1756284818811508. (PMID: 30479664)
BMC Gastroenterol. 2006 Nov 10;6:34. (PMID: 17096854)
Ultrasound Med Biol. 2018 Dec;44(12):2419-2440. (PMID: 30209008)
Hepatol Commun. 2017 Sep;1(7):609-622. (PMID: 29130075)
World J Hepatol. 2015 Feb 27;7(2):226-34. (PMID: 25729477)
J Med Life. 2018 Jul-Sep;11(3):243-246. (PMID: 30364513)
Mol Aspects Med. 2017 Aug;56:34-44. (PMID: 28442273)
Hepatol Int. 2013 Aug 30;7 Suppl 2:771-81. (PMID: 24587847)
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6807-13. (PMID: 25400762)
Biomark Insights. 2012;7:159-66. (PMID: 23440040)
Hepatology. 2019 Mar;69(3):1075-1086. (PMID: 30014517)
BMC Gastroenterol. 2010 Jun 28;10:67. (PMID: 20584330)
Radiology. 2015 Dec;277(3):881-6. (PMID: 26147680)
Hepatology. 2005 Dec;42(6):1373-81. (PMID: 16317693)
AJR Am J Roentgenol. 2015 Jul;205(1):33-40. (PMID: 25905762)
Theranostics. 2017 Mar 7;7(5):1303-1329. (PMID: 28435467)
Liver Int. 2009 Nov;29(10):1507-15. (PMID: 19725892)
Cell Metab. 2012 May 2;15(5):665-74. (PMID: 22560219)
J Proteome Res. 2012 Aug 3;11(8):4052-64. (PMID: 22694338)
Biotechnol Bioeng. 2005 Aug 20;91(4):502-15. (PMID: 15918168)
J Hepatol. 2012 Jan;56(1):241-7. (PMID: 21756851)
Am J Physiol Gastrointest Liver Physiol. 2016 Dec 1;311(6):G1009-G1017. (PMID: 27765759)
World J Gastroenterol. 2014 Aug 21;20(31):10851-63. (PMID: 25152587)
J Gastroenterol. 2007 Jul;42(7):573-82. (PMID: 17653654)
Hepatology. 2009 Dec;50(6):1827-38. (PMID: 19937697)
Oxid Med Cell Longev. 2018 Jun 11;2018:9547613. (PMID: 29991976)
Liver Int. 2017 Jul;37(7):1065-1073. (PMID: 27778429)
Gut. 2010 Sep;59(9):1245-51. (PMID: 20675693)
Evid Based Complement Alternat Med. 2015;2015:715638. (PMID: 26221176)
Med Sci Monit. 2012 Dec;18(12):CR735-40. (PMID: 23197236)
Dig Dis Sci. 2018 Sep;63(9):2259-2266. (PMID: 29779083)
BMC Gastroenterol. 2012 Jan 05;12:2. (PMID: 22221544)
N Engl J Med. 2006 Jun 15;354(24):2552-63. (PMID: 16775236)
Gastroenterology. 2001 Jul;121(1):91-100. (PMID: 11438497)
Proteomics Clin Appl. 2010 Apr;4(4):362-71. (PMID: 21137056)
Acta Histochem. 2010 Sep;112(5):474-81. (PMID: 19604544)
Liver Int. 2015 Jun;35(6):1673-81. (PMID: 25495373)
BMC Gastroenterol. 2011 Aug 17;11:91. (PMID: 21849046)
Lab Invest. 2012 Dec;92(12):1712-25. (PMID: 23007134)
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt A):1024-1036. (PMID: 29329986)
Alcohol Clin Exp Res. 2010 Nov;34(11):1937-47. (PMID: 20682011)
J Hepatol. 2009 Jan;50(1):165-73. (PMID: 18977552)
Am J Transl Res. 2013 Apr 19;5(3):303-15. (PMID: 23634241)
Liver Int. 2016 Apr;36(4):572-9. (PMID: 26713759)
Liver Int. 2013 Mar;33(3):439-47. (PMID: 23279004)
J Hepatol. 2011 Jan;54(1):160-3. (PMID: 20934232)
PLoS Pathog. 2015 Jan 27;11(1):e1004559. (PMID: 25625278)
Radiology. 2015 Sep;276(3):845-61. (PMID: 26079489)
Metabolism. 2013 Mar;62(3):392-9. (PMID: 23036645)
Hepatology. 2011 Jan;53(1):325-35. (PMID: 21254180)
J Biol Chem. 2004 Sep 17;279(38):39431-7. (PMID: 15262986)
Aliment Pharmacol Ther. 2012 Mar;35(5):600-12. (PMID: 22403816)
J Pediatr Gastroenterol Nutr. 2017 Apr;64(4):512-517. (PMID: 27540711)
J Gastroenterol Hepatol. 2006 Sep;21(9):1459-65. (PMID: 16911693)
World J Gastroenterol. 2014 Apr 28;20(16):4787-96. (PMID: 24782633)
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. (PMID: 29307986)
Hepatology. 2007 Apr;45(4):846-54. (PMID: 17393509)
BMC Cancer. 2009 Aug 05;9:271. (PMID: 19656391)
Mol Cell. 2004 Sep 10;15(5):713-25. (PMID: 15350216)
Curr Pathobiol Rep. 2014 Sep 1;2(3):109-115. (PMID: 25574453)
Curr Opin HIV AIDS. 2010 Nov;5(6):463-6. (PMID: 20978388)
Aliment Pharmacol Ther. 2013 Nov;38(9):1086-96. (PMID: 24099470)
Gastroenterology. 2008 Jul;135(1):32-40. (PMID: 18471441)
Exp Mol Pathol. 2011 Oct;91(2):603-7. (PMID: 21791204)
Adv Pharmacol. 2015;74:263-302. (PMID: 26233910)
Horm Metab Res. 2012 Jan;44(1):6-14. (PMID: 22205567)
Hepatobiliary Surg Nutr. 2017 Apr;6(2):117-121. (PMID: 28503559)
Hepatology. 2011 Jul;54(1):344-53. (PMID: 21520200)
Clin Chem. 2005 Oct;51(10):1867-73. (PMID: 16055434)
J Hepatol. 2014 Jan;60(1):69-77. (PMID: 24036007)
Mol Cell Biochem. 2007 May;299(1-2):75-84. (PMID: 17001451)
Dig Dis Sci. 2016 May;61(5):1356-64. (PMID: 27017224)
PLoS One. 2013 Jun 21;8(6):e66328. (PMID: 23805214)
Lancet. 2015 Mar 14;385(9972):956-65. (PMID: 25468160)
Endocrinol Metab (Seoul). 2018 Mar;33(1):33-43. (PMID: 29589386)
Hepatology. 2003 Aug;38(2):518-26. (PMID: 12883497)
Hepatology. 2017 Jan;65(1):65-77. (PMID: 27532276)
Hepatology. 2006 Jun;43(6):1317-25. (PMID: 16729309)
Hepatology. 2003 Nov;38(5):1136-45. (PMID: 14578852)
Hepatology. 2010 Jan;51(1):111-20. (PMID: 19885878)
Can J Gastroenterol Hepatol. 2016;2016:6489012. (PMID: 27446858)

0 (Biomarkers)
0 (Circulating MicroRNA)

Date Created: 20200115 Date Completed: 20200629 Latest Revision: 20200629

20221213

10.1007/s40290-019-00305-z

31933238